Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 72Ovarian Neoplasms 46Breast Neoplasms 27Lung Neoplasms 26Fallopian Tube Neoplasms 23Small Cell Lung Carcinoma 18Carcinoma, Ovarian Epithelial 16Squamous Cell Carcinoma of Head and Neck 14Neoplasms 14Triple Negative Breast Neoplasms 13Glioblastoma 13Recurrence 11Head and Neck Neoplasms 11Lymphoma, Large B-Cell, Diffuse 10Endometrial Neoplasms 10Uterine Cervical Neoplasms 9Colorectal Neoplasms 9Stomach Neoplasms 8Hodgkin Disease 8Brain Neoplasms 8Lymphoma 7Esophageal Neoplasms 7Central Nervous System Neoplasms 7Prostatic Neoplasms 6Neoplasm Metastasis 6Glioma 6Esophageal Squamous Cell Carcinoma 6Astrocytoma 6Adenocarcinoma of Lung 6Mesothelioma 5

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Carboplatin × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡